A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma
Estimate the maximum tolerated dose (MTD) of human hsp110-gp100 chaperone complex melanoma vaccine to recommend a Phase II dose in Stage IIIB/C and Stage IV metastatic melanoma patients. To quantify patient characteristics that may correlate with immune response to the chaperone complex vaccine.
Study Number: 

I 215912

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.